Pre-surgery low-dose azacitidine for high-risk early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether giving a low dose of azacitidine before surgery can shrink or control high-risk early breast cancer. It’s meant for adults whose cancer has not yet spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent for the study
- You can move about normally (ECOG 0–2)
- Your breast cancer was confirmed by biopsy and is early stage (T1a–T3, no distant spread)
- Your tumor is either triple-negative breast cancer, or hormone-receptor positive but with high-risk features (like HER2, lymph node involvement, certain gene tests, or PR-negative)
- Your blood counts and liver/kidney tests are adequate, checked within 30 days of enrolling
- You have not had cancer treatment for this current breast cancer (like chemo, immunotherapy, radiation to the breast/underarm area)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
This Phase 1/2 trial tests different combinations that include azacitidine, chosen based on your tumor’s lab “response markers” and past drug-sensitivity screening. It aims to find safer dosing and see whether these personalized combinations can shrink solid tumors such as breast or stomach cancer.
This Phase 2 study tests a faster, more frequent chemotherapy schedule given before surgery (neoadjuvant therapy) for certain breast cancers that grow quickly. It may help shrink the tumor before the operation and improve treatment response in people who fit the tumor and health criteria.
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.